Importantly, our findings reinforce that the antihypertensive effect of SGLT-2 inhibitors is evident in both diabetic and non-diabetic hypertensive patients, supporting evidence from the DECLARE-TIMI 58 and DAPA-HF trials [14], which demonstrated beneficial effects even in patients without diabetes. Here, SLC5A2 is linked to hydrops fetalis.